

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroPort CardioFlow Medtech Corporation

微创心通医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2160)

POLL RESULTS OF EXTRAORDINARY GENERAL MEETING HELD ON DECEMBER 15, 2025

References are made to the circular dated November 24, 2025 (the “**Circular**”) incorporating, amongst others, the notice dated November 24, 2025 (the “**EGM Notice**”) of the extraordinary general meeting (the “**EGM**”) and supplement announcement dated November 25, 2025 of MicroPort CardioFlow Medtech Corporation (the “**Company**”). Unless otherwise stated, capitalised terms used herein shall have the same meanings as those defined in the Circular and the EGM Notice.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that at the EGM held on December 15, 2025, the proposed resolution as set out in the EGM Notice was duly approved by the Shareholders by way of poll.

As of the date of the EGM, the total number of issued Shares was 2,412,706,775 Shares. There was no treasury shares (as defined under the Listing Rules) held by the Company (including any treasury shares held or deposited with the Central Clearing and Settlement System established and operated by Hong Kong Securities Clearing Company Limited) and as such no voting rights of treasury shares have been exercised at the EGM. As stated in the Circular, (i) MicroPort Scientific Corporation (through its wholly-owned subsidiary Shanghai MicroPort Limited, indirectly holding 1,112,855,680 Shares, representing approximately 46.12% of the issued Shares of the Company as of the date of the EGM) and its associates were required to abstain, and had abstained from voting on ordinary resolution numbered 1 at the EGM, (ii) Worldstar Global Holdings Limited, being one of the Remaining Shareholders, (representing approximately 0.003% of the issued Shares of the Company as of the date of the EGM), and (iii) Mr. Zhao Liang (趙亮), (representing approximately 0.07% of the issued Shares of the Company as of the date of the EGM), had also abstained from voting on the ordinary resolution numbered 1 at the EGM pursuant to Rule 2.15 of the Listing Rules. Save as disclosed above, no Shareholders were required under the Listing Rules to abstain from voting on any of the resolutions at the EGM and no Shareholders were entitled to attend and abstain from voting in favor as set out in Rules 13.40 and 14A.36 of the Listing Rules. Save as disclosed above, no Shareholders have

stated their intention in the Circular to vote against or to abstain from voting on any of the proposed resolution at the EGM.

The Company's share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the EGM for the purpose of vote-taking.

All the Directors, namely Mr. Zhang Ruinian, Mr. Zhao Liang and Ms. Yan Luying as the executive Directors, Mr. Chen Guoming, Mr. Zhang Junjie and Ms. Wu Xia as the non-executive Directors, and Mr. Jonathan H. Chou, Ms. Sun Zhixiang and Dr. Hu Bingshan as the independent non-executive Directors attended the EGM in person or by electronic means.

The poll results of the resolution proposed at the EGM was as follow:

ORDINARY RESOLUTION		Number of Votes (%)	
		For	Against
1	<p>(a) the merger agreement dated 29 September 2025 (the “Merger Agreement”) entered into between the Company, MicroPort CardioFlow CRM Limited (the “Merger Sub”) and MicroPort Cardiac Rhythm Management Limited (the “Target Company”) (a copy of which marked “A” has been produced to the EGM and initialed by the chairman of the EGM for the purpose of identification) in relation to, among other matters, the proposed merger between the Target Company and the Merger Sub under section 233 of the Cayman Companies Act (the “Merger”), and the transactions contemplated thereunder be and are hereby approved, ratified and confirmed;</p> <p>(b) subject to and conditional upon the fulfilment or waiver of the conditions precedent set out in the Merger Agreement, the Directors be and are hereby granted a specific mandate to exercise the powers to allot and issue a total of 3,953,847,407 new ordinary shares of the Company (the “New Shares”) at the issue price of HK\$1.35 each to the relevant shareholder of the Target Company at completion of the Merger in accordance with the terms and conditions of the Merger Agreement; and</p>	<p>520,067,620 99.994232%</p>	<p>30,000 0.005768%</p>

ORDINARY RESOLUTION		Number of Votes (%)	
		For	Against
	(c) subject to and conditional upon the fulfilment or waiver of the conditions precedent set out in the Merger Agreement, any one or more Directors be and is/are hereby authorised, for and on behalf of the Company, to execute all such documents, instruments and agreements, and take such action, do all such acts or things, as he/she/they may, in his/her/their absolute discretion, consider necessary, appropriate, desirable or expedient for the purpose of, or in connection with, the implement of or giving effect or completion of any matters relating to the Merger Agreement and the transaction contemplated thereunder, the issue and allotment of the New Shares, and all matters incidental thereto.		

Note: The full text of the above resolutions are set out in the EGM Notice.

As more than 50% of votes were cast in favour of the ordinary resolution no. 1 above, such resolution was duly passed by the Shareholders as ordinary resolution.

Shareholders and potential investors of the Company should note that the completion of the Merger had yet to take place. Shareholders and potential investors are advised to exercise caution when dealing in the Shares and securities of the Company.

By Order of the Board
MicroPort CardioFlow Medtech Corporation
Chen Guoming
Chairman

Shanghai, PRC, December 15, 2025

As of the date of this announcement, the executive Directors are Mr. Zhang Ruinian, Mr. Zhao Liang and Ms. Yan Luying, the non-executive Directors are Mr. Chen Guoming, Mr. Zhang Junjie and Ms. Wu Xia, and the independent non-executive Directors are Mr. Jonathan H. Chou, Ms. Sun Zhixiang and Dr. Hu Bingshan.